Late diagnosis in adolescence of vertically acquired HIV infection

HIV Treat Bull - 2008 July-August;9(7/8):

Polly Clayden, HIV i-Base

In an oral presentation, M Prime and coworkers presented findings from an investigation of clinical characteristics and circumstances in a group of vertically infected adolescents diagnosed in the UK or Ireland at 13 years of age or above. This study was conducted by investigators from: St George’s Hospital, London, London School of Hygiene and Tropical Medicine, St Mary’s Hospital, London, MRC Clinical Trials Unit, UCL Institute of Child Health and Mortimer Market Centre, London.

In the UK and Ireland, HIV positive children diagnosed at <16 years of age are reported to the National Study of HIV in Pregnancy and Childhood and followed up through the Collaborative HIV Paediatric Study. New HIV diagnoses made at adult services are reported to the Health Protection Agency and the Survey of Prevalent HIV Infections Diagnosed collects annual data on patients receiving care.

This study was an analysis of data to the end of 2005.

The investigators identified 38 cases; of these 19 (50%) were male and 36 (95%) were black African. 34 (89%) were born in sub-Saharan Africa, and three of these were diagnosed before arrival in the UK/Ireland.

The median age of the adolescents at diagnosis was 14.3 years (IQR: 13.6–15 years) with a median of 1.8 years (IQR: 0.2–5.6 years) between arrival in the UK and HIV diagnosis. 24 (63%) of those diagnosed presented with symptoms; the others were tested for HIV as part of screening for STIs or following diagnosis of a family member. Their median CD4 count at diagnosis was 208 cells/mm³ (IQR: 23–251 cells/mm³) and 11 developed AIDS before or within 2 years of diagnosis.

Thirty two patients began antiretroviral therapy (ART), the majority (88%) within a year of their HIV diagnosis.

The investigators wrote: “Young people with vertically acquired HIV infection are surviving childhood without ART and being diagnosed in adolescence. In this cohort a third were asymptomatic, highlighting the importance of testing all children born to HIV infected women, regardless of age or symptoms.” They added: “Increased awareness amongst clinicians is urgently required to prevent presentation with advanced disease and to reduce ongoing transmission as this population become sexually active.”

Reference:

Prime K, Ferrand R, Foster C et al. First presentation of vertically acquired HIV infection in adolescence. HIV Med 2008; 9(Suppl. 1):1 (abstract no. O2).

2008-07-10
IB080907-03b

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.